These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17516484)

  • 21. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Entacapone: is it useful as complimentary treatment with levodopa?].
    Burguera JA; Grandas F; Horga de la Parte JF; Luquin R; Martí F; Matías-Guiu J; Obeso JA; Kulisevsky J
    Rev Neurol; 1999 Apr 16-30; 28(8):817-34. PubMed ID: 10363328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
    Kupsch A; Trottenberg T; Bremen D
    Curr Med Res Opin; 2004 Jan; 20(1):115-20. PubMed ID: 14741081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
    Rascol O; Bronzova J; Hauser RA; Lang AE; Sampaio C; Theeuwes A; van de Witte SV
    Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of high-dose cabergoline in Parkinson's disease.
    Odin P; Oehlwein C; Storch A; Polzer U; Werner G; Renner R; Shing M; Ludolph A; Schüler P
    Acta Neurol Scand; 2006 Jan; 113(1):18-24. PubMed ID: 16367894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pooled analysis of phase III with entacapone in Parkinson's disease.
    Kuoppamäki M; Vahteristo M; Ellmén J; Kieburtz K
    Acta Neurol Scand; 2014 Oct; 130(4):239-47. PubMed ID: 25186800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.
    Entacapone to Tolcapone Switch Study Investigators
    Mov Disord; 2007 Jan; 22(1):14-9. PubMed ID: 17089403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
    Destée A; Rérat K; Bourdeix I
    Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
    Marin C; Aguilar E; Obeso JA
    Mov Disord; 2006 May; 21(5):646-53. PubMed ID: 16437585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD; Dubini A; Orlando N; Grimaldi R
    Neurology; 1997 Feb; 48(2):363-8. PubMed ID: 9040722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study.
    Zangaglia R; Stocchi F; Sciarretta M; Antonini A; Mancini F; Guidi M; Martignoni E; Pacchetti C
    Clin Neuropharmacol; 2010; 33(2):61-6. PubMed ID: 19935405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
    Luer MS
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):169S-79S. PubMed ID: 10555945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.
    Trenkwalder C; Benes H; Grote L; Happe S; Högl B; Mathis J; Saletu-Zyhlarz GM; Kohnen R;
    Mov Disord; 2007 Apr; 22(5):696-703. PubMed ID: 17274039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurostimulation for Parkinson's disease with early motor complications.
    Schuepbach WM; Rau J; Knudsen K; Volkmann J; Krack P; Timmermann L; Hälbig TD; Hesekamp H; Navarro SM; Meier N; Falk D; Mehdorn M; Paschen S; Maarouf M; Barbe MT; Fink GR; Kupsch A; Gruber D; Schneider GH; Seigneuret E; Kistner A; Chaynes P; Ory-Magne F; Brefel Courbon C; Vesper J; Schnitzler A; Wojtecki L; Houeto JL; Bataille B; Maltête D; Damier P; Raoul S; Sixel-Doering F; Hellwig D; Gharabaghi A; Krüger R; Pinsker MO; Amtage F; Régis JM; Witjas T; Thobois S; Mertens P; Kloss M; Hartmann A; Oertel WH; Post B; Speelman H; Agid Y; Schade-Brittinger C; Deuschl G;
    N Engl J Med; 2013 Feb; 368(7):610-22. PubMed ID: 23406026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
    Giladi N; Tal J; Azulay T; Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe WH; Stocchi F; Tolosa E
    Mov Disord; 2009 Apr; 24(5):655-61. PubMed ID: 19127595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.